Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of weekly MOD-4023 versus placebo in adults with growth hormone deficiency
NL-OMON38522Phase 3Withdrawn
- Sponsor
- OPKO Biologics
- Start
- Jul 2013
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in growth hormone deficiency (GHD) comparing MOD-4023 weekly with Placebo weekly (2 arms). Primary endpoint: Change in trunk fat mass at week 26. Planned start Jul 2013; status: withdrawn.
02
Drugs
somatrogon
03
Conditions
growth hormone deficiency (GHD)
Beyond the preview
Go deeper on NL-OMON38522.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON38522.